Stockscreener 앱 받기
1.24
8.82%
-0.12
시간 외 거래:
1.34
0.10
+8.06%
전일 마감가:
$1.36
열려 있는:
$1.41
하루 거래량:
180.71K
Relative Volume:
0.06
시가총액:
$2.98M
수익:
-
순이익/손실:
$-18.35M
주가수익비율:
-
EPS:
-
순현금흐름:
$-19.20M
1주 성능:
-33.33%
1개월 성능:
-16.78%
6개월 성능:
-99.46%
1년 성능:
-99.52%
1일 변동 폭
$1.24
$1.43
1주일 범위
$1.24
$1.80
52주 변동 폭
$1.24
$427.81
Theriva Biologics Inc Stock (TOVX) Company Profile
명칭
Theriva Biologics Inc
전화
301 417 4364
주소
9605 Medical Center Drive, Suite 270, Rockville
TOVX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TOVX | 1.24 | 2.98M | 0 | -18.35M | -19.20M | 0.00 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Theriva Biologics Inc 주식(TOVX)의 최신 뉴스
Synthetic Biologics stock hits 52-week low at $1.24 By Investing.com - Investing.com South Africa
Maxim Group Has Lowered Expectations for Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price - Defense World
Theriva Biologics Highlights Key Achievements in Q3 2024 - TipRanks
Theriva Biologics: Q3 Earnings Snapshot - Houston Chronicle
Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial Results - GlobeNewswire
Theriva Biologics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
What's Going On With Theriva Biologics Stock Friday? - MSN
Theriva Biologics Expands Stock Plans and Share Authority - TipRanks
Theriva Biologics seleccionada como finalista en el concurso internacional para las becas del programa Advance Biotech Grant en la región EMEA de Merck KGaA - GlobeNewswire Inc.
Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech Grant - The Manila Times
Theriva Biologics gains EU orphan drug status for eye cancer treatment - Investing.com
Theriva Biologics Announces Orphan Medicinal Product - GlobeNewswire
Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma - StockTitan
Check out these key findings about Theriva Biologics Inc (TOVX) - SETE News
Theriva Biologics Inc: A Comprehensive Look at the Stock’s Ups and Downs - The InvestChronicle
Was Theriva Biologics Inc (TOVX)’s session last reading good? - US Post News
Market cap of Theriva Biologics Inc [TOVX] reaches 4.06M – now what? - The DBT News
Closing Figures: Theriva Biologics Inc (TOVX)’s Positive Finish at 1.79, Up 44.35 - The Dwinnex
Theriva reports progress in phase 1b/2a trial of SYN-004 By Investing.com - Investing.com South Africa
Synthetic Biologics stock plunges to 52-week low of $1.24 By Investing.com - Investing.com Australia
Theriva reports progress in phase 1b/2a trial of SYN-004 - Investing.com Australia
OMER Stock Falls 5.35% Amid Mixed Institutional Ratings - GuruFocus.com
Halozyme (HALO) Stock Surges Amid Positive Earnings and Analyst Ratings - GuruFocus.com
Crude Oil Jumps Over 4%; US Services PMI Revised Lower - Benzinga
Nano-Cap Theriva Biologics' Investigational Drug For Transplant-Related Complication Shows Safety In Bone Marrow Transplant Patients - Benzinga
Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients - Seeking Alpha
Theriva Biologics Advances SYN-004 in Clinical Trial - TipRanks
Theriva™ Biologics Announces Positive Outcome of Data and Safety Monitoring Committee (DSMC) Review in Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients - The Manila Times
Theriva™ Biologics Announces Positive Outcome of Data and - GlobeNewswire
Synthetic Biologics stock plunges to 52-week low of $1.24 - Investing.com India
Was anything negative for Theriva Biologics Inc (TOVX) stock last session? - US Post News
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket - MSN
Theriva Biologics dips 11%, prices 2.5M equity offering - MSN
Theriva Biologics Announces Pricing of $2.5 Million Public Offering - StockTitan
Theriva Biologics Inc (TOVX) Stock: From Low to High in 52 Weeks - The InvestChronicle
Understanding TOVX stock ratios for better investment decisions - US Post News
Synthetic Biologics stock plunges to 52-week low of $2.66 - Investing.com
Telesis Bio Inc (TBIO) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
TRxADE Health rebrands as Scienture Holdings with new ticker SCNX - Investing.com
An Analysis of Theravance Biopharma Inc (TBPH)’s Potential Price Growth - Knox Daily
Market Recap: Trupanion Inc (TRUP)’s Positive Momentum, Closing at 42.80 - The Dwinnex
Interval Partners LP Makes New $10.41 Million Investment in TransDigm Group Incorporated (NYSE:TDG) - Defense World
Investing in Hercules Capital Inc (HTGC): What You Must Know - Knox Daily
Morse Asset Management Inc Invests $701,000 in Hercules Capital, Inc. (NYSE:HTGC) - MarketBeat
Theriva Biologics Advances VCN-01 in VIRAGE Phase 2b Trial - TipRanks
Theriva™ Biologics Achieves Target Patient Enrollment in - GlobeNewswire
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer - StockTitan
Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with… - Informazione.it
Thryv Holdings, Inc. (NASDAQ:THRY) Shares Acquired by Harspring Capital Management LLC - Defense World
Harspring Capital Management LLC Purchases 30,000 Shares of Thryv Holdings, Inc. (NASDAQ:THRY) - MarketBeat
Hancock Whitney Corp Cuts Position in Tenet Healthcare Co. (NYSE:THC) - Defense World
Theriva Biologics Inc (TOVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):